All In Biotech

Free tool

FAERS Monitor: Nivestym

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761080 or its brand name (Nivestym, Filgrastim-Aafi). Reports on generic versions are filed under their own applications.

Reports

669

Serious

400

60% of reports

Hospitalization

190

Death reported

116

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death94
  • off label use84
  • white blood cell count decreased38
  • pyrexia25
  • hospitalisation24
  • fatigue23
  • diarrhoea22
  • pain21
  • malaise19
  • device leakage18
  • needle issue18
  • bone pain17
  • dyspnoea17
  • product dose omission issue17
  • infection15

Reports by year received

View as table
YearReports
201924
202066
202177
2022106
2023122
202499
202593
202682

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,490 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
needle issueSignal1819.512.3297
device leakageSignal1813.18.3189
white blood cell count decreasedSignal3811.08.1338
bone painSignal179.15.7115
hospitalisationSignal244.93.371
deathSignal943.42.8166
infectionSignal153.32.021
off label useSignal843.02.5116
pyrexiaSignal252.31.517
product dose omission issue171.81.16
malaise191.40.92
pain211.10.70
diarrhoea221.10.70
dyspnoea170.90.60
fatigue230.90.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.